Extra checks for breast cancer in pregnancy needed

June 20, 2003

NOT FOR RELEASE BEFORE 12.00 BST, FRIDAY, 20 JUNE 2003

Obstetricians should perform a thorough breast examination of pregnant women to detect breast cancer, according to a study presented today (20 June). Too often the diagnosis is delayed because doctors and pregnant women assume that lumps in the breast are due to normal hormonal changes.

The threat of breast cancer is frightening for anyone, particularly during pregnancy, but it is not uncommon. Around one in every thousand women gets breast cancer every year. Pregnant women and physicians should be more aware of the risk of cancer. Speaking at the European Society for Medical Oncology conference in Edinburgh, Dr Blanca Hernando from the University Hospital Clinic in Valencia, Spain, said, "The obstetrician is usually more focused on the health of the unborn baby than the mother's possible illness but should be more aware of the risk of breast cancer." Women should examine their breasts regularly and tell their doctor about any changes they discover.

Not only is diagnosis often delayed, but there is a high rate of false-negative results of a mammography due to the increased density of the breast during pregnancy.

Ultrasonogaphy is the best way to check for cancerous lumps in pregnant and lactating women. Many studies have shown that the tumours in pregnant women are larger and are more likely to spread.

Pregnant women should be encouraged to know that treatment is as successful and safe as in non-pregnant women. Surgery is the best route although there is a small risk of premature labour. Radiation therapy is not offered during pregnancy but patients can be safely treated with certain forms of chemotherapy from three months onwards. This may be continued after the baby is born, although mothers should not breast feed their babies while they are having chemotherapy.

In a study of 18 women with breast cancer, Dr Hernando reported that there was a 10- week delay in the diagnosis meaning that patients were treated when their cancer had progressed. All the patients had surgery to remove the lump and chemotherapy. Four women diagnosed in the first three months chose to have an abortion and another four patients needed a caesarean. All the babies born were healthy.

"Breast cancer during pregnancy has about the same prognosis as other breast cancer, when compared to women of a similar age," said Dr Hernando. "It is, of course, a very serious illness but it can be treated successfully. The most important thing is to be diagnosed and treated at an early stage to prevent it spreading to other parts of the body."
-end-
For further information contact:

Edinburgh Press Office: Room Ochil Tel ++44 (0)131 519 4131 Fax ++44 (0)131 519 4140

Opening times: Thursday, 19 June from 13.00-17.00 Friday, 20 June from 08.00-18.00 Saturday, 21 June from 08.00-19.00 Sunday, 22 June from 08.00-16.00

At other times, please contact: Gracemarie Bricalli, ESMO Media Coordinator: Tel. ++41 (0)91 973 19 11, Fax ++41 (0)91 973 19 12 Mobile ++41 (0)79 778 5177, gracemarie@esmo.org

Notes to Editors
About the European Society for Medical Oncology (ESMO)
ESMO believes that every cancer patient is entitled to the best possible treatment available. Since medicine is involved in every aspect of cancer therapy, cancer patients need to be treated by qualified medical oncologists. ESMO is the leading European Society that provides education and guidelines for medical oncologists to ensure optimal care for cancer patients. Its official scientific journal is Annals of Oncology. Since 1975, the Society has grown to include representatives from every European country and the six major geographical regions of the world. More information about the Society can be obtained at www.esmo.org.

The ESMO Summer Educational Conference (ESEC) takes place in Edinburgh, Scotland, UK - 19 - 22 June 2003.

Abstract 49PD - Discussion Time: 10.00-10.45, Sunday, 22 June 2003, Fintry Suite

Management of Breast Cancer during pregnancy

Blanca Hernando Fernandez de Aranguiz (1) (1) Servicio Oncologia y Hematologia medica, Hospital Clinico universitario, Valencia, Spain

To review the management of breast cancer during pregnancy, we present our experience with the use of combination chemotherapy. Patients and methods: 4784 women with stage I-IV breast cancer were diagnosed since October 1982 to July-2002. A total of 18 women (0.0037%) were diagnosed of breast cancer during pregnancy. All were managed by outpatient chemotherapy, surgery and radiation therapy as clinically indicated. Chemotherapy included antracyclines after the first trimester of pregnancy. Median age was 35 years old (29-41). Patients were diagnosed: 4/18 in the first trimester, 5/18 at the second trimester, 3/18 at the third trimester and 6/18 in the postpartum period. Delay in diagnosis was 2,5 months (1-8). They were 55 % stage III-IV. 66% node positive tumors. 50% had negative estrogen and /or progesterone receptors status. 88% were invasive ductal carcinoma. 22% were inflammatory carcinomas. 7 of 9 evaluated tumor had high nuclear grade (II or III). 6/9 evaluated tumor had overexpression of the Her-2/neu. All patients had surgical treatment (with radical mastectomy in 77%). Postpartum radiation therapy was administered in 66%. All patients received chemotherapy including antracyclines, 31% during the second and third trimester and 66% in the postpartum period. No anterpartum complications attributable to systemic therapy were noted. Four patients required cesarean. Immediate postpartum health was reported to be normal for all the children. Four patients diagnosed and informed of the risk of treatment during first trimester, choose therapeutic abortion. Median follow-up was 34 months. Seven patients still remain progression free survival. 3-year survival was estimated at 65%. For the matched comparison nonpregnant women group, survival was 66%. Conclusions:3-year survival is similar to that for nonpregnant women when adjusted for age. Breast cancer can be safely treated with chemotherapy including antracyclines during the second and third trimesters of pregnancy without complications.

Blanca HERNANDO FERNÁNDEZ DE ARÁNGUIZ

Curriculum Vitae

Academic training: MD Degree from 1993-1999 at University of Navarra, Pamplona

Medical Oncology Degree: Training period from 2000-2003, at the Haematology and Medical Oncology Department of the University Hospital Valencia

Doctorate Courses: Metodología de la investigación, Hematología y Oncología

Congresses attended: Advanced Ovarian cancer, optimal therapy update (ESMO/MORA) 28-02-2003. Simposio en avances y nuevas perspectivas en neoplasias hematológicas; Colorectal reviews; Breast cancer surgical and medical treatment symposium

Research projects Co-investigator: Phase II trial of Vinflunina in patients with advanced ovarian cancer unresponsive to chemotherapy based on platinum/taxanes. Protocol 0L00071N208E2

Collaborate investigator: Investigation project at University Hospital Valencia: "Predictive factors in response to Darbopoetin alfa in patients with lung cancer receiving chemotherapy with platinum".

European Society for Medical Oncology

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.